Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes - Hayato, Seiichi; Hasegawa, Setsuo; Hojo, Seiichiro; Okawa, Hiroki; Abe, Hiroaki; Sugisaki, Nobuyuki; Munesue, Masahiro; Horai, Yukio; Ohnishi, Akihiro (European journal of clinical pharmacology, 2012)
Keywords: 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage; 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects; 2-Pyridinylmethylsulfinylbenzimidazoles - blood; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology; Adult; Anti-Ulcer Agents - administration & dosage; Aryl Hydrocarbon Hydroxylases - genetics; Aryl Hydrocarbon Hydroxylases - metabolism; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Circadian Rhythm; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Double-Blind Method; Gastric Acid - metabolism; Gastric Mucosa - drug effects; Gastric Mucosa - metabolism; Genotype; Half-Life; Humans; Japan; Male; Medical sciences; Models, Biological; Pharmacodynamics; Pharmacology. Drug treatments; Pharmacology/Toxicology; Polymorphism, Genetic; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - adverse effects; Proton Pump Inhibitors - blood; Proton Pump Inhibitors - pharmacology; Rabeprazole; Young Adult; Asia; Japan; CYP2C19 genotype; GERD; Pharmacodynamics; Nocturnal gastric pH; Rabeprazole; Pharmacokinetics; Night; Isozyme; H; Antiulcer agent; K; Proton pump inhibitor; Dose activity relation; pH; Single daily dose; Human; Stomach; Healthy subject; Digestive system; Enzyme; Secretion; Cytochrome P450; Enzyme inhibitor; Genotype; CYP2C 19 genotype; Biological activity; Acids; Benzimidazole derivatives; exchanging ATPase; Hydrolases; Daily dose